Back to top
more

CytomX Therapeutics (CTMX)

(Delayed Data from NSDQ)

$1.05 USD

1.05
1,448,351

+0.05 (5.45%)

Updated Nov 1, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

CytomX Therapeutics (CTMX) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

CytomX Therapeutics (CTMX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why CytomX Therapeutics (CTMX) Stock Might be a Great Pick

by Zacks Equity Research

CytomX Therapeutics (CTMX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Here's Why CytomX Therapeutics (CTMX) is a Great Momentum Stock to Buy

by Zacks Equity Research

Does CytomX Therapeutics (CTMX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Top Ranked Momentum Stocks to Buy for April 17th

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 17th

CytomX Therapeutics (CTMX) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

CytomX Therapeutics (CTMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Will CytomX Therapeutics Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor CytomX Therapeutics

Top Ranked Momentum Stocks to Buy for April 3rd

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 3rd

CytomX & Astellas Collaborate to Develop Novel Cancer Therapy

by Zacks Equity Research

CytomX (CTMX) and Astellas Pharma sign collaboration agreement to develop novel cancer therapy using CytomX's Probody therapeutic technology platform.

CytomX Therapeutics (CTMX) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -43.64% and -47.24%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

CytomX Therapeutics (CTMX) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

CytomX Therapeutics (CTMX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Will CytomX Therapeutics (CTMX) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

CytomX Therapeutics (CTMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -16.36% and -40.34%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: CytomX Therapeutics (CTMX) Q2 Earnings Expected to Decline

by Zacks Equity Research

CytomX Therapeutics (CTMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CytomX Therapeutics (CTMX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of 41.51% and 116.96%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate CytomX Therapeutics (CTMX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

CytomX Therapeutics (CTMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate CytomX Therapeutics (CTMX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

CytomX Therapeutics (CTMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CytomX Therapeutics Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in CytomX Therapeutics.

CytomX Therapeutics (CTMX) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -26.19% and -23.81%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: CytomX Therapeutics (CTMX) Q3 Earnings Expected to Decline

by Zacks Equity Research

CytomX Therapeutics (CTMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CytomX Therapeutics (CTMX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -2.94% and 29.52%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

    Amgen Enters Into an Immuno-Oncology Partnership With CytomX

    by Zacks Equity Research

    Amgen (AMGN) has entered into a strategic immuno-oncology collaboration with CytomX to jointly develop a T-cell engaging bispecific probody.

      Should CytomX Therapeutics (CTMX) Be On Your Radar Now?

      by Zacks Equity Research

      CytomX Therapeutics (CTMX) seems to be overlooked by shareholders as its favorable estimate revisions are not well reflected by its share price performance.

        Bristol-Myers Squibb and CytomX Therapeutics Extend Deal

        by Zacks Equity Research

        Bristol-Myers Squibb Company (BMY) and CytomX Therapeutics, Inc. (CTMX), announced an expansion of their 2014 strategic collaboration to discover novel therapies.